Tocilizumab Dosing Study for Rheumatoid Arthritis
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study measures how tocilizumab (an arthritis medication) works in your body when given as an infusion. You qualify if you have rheumatoid arthritis that hasn't fully responded to other treatments but is now under control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with rheumatoid arthritis using standard medical criteria
- Your arthritis is currently in low activity or remission (well-controlled)
- Previous treatment with other arthritis medications didn't work well enough
- Scheduled to receive tocilizumab 8mg/kg infusion as part of your care
- No active cancer or history of bowel perforation/diverticulitis
- Willing to maintain stable doses of other arthritis medications for at least 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called CIT-013 for people with rheumatoid arthritis. It aims to see if CIT-013 can help reduce joint swelling and pain when added to your current treatment.
This study tests a combination of two drugs (telitacicept and baricitinib) for people with stubborn rheumatoid arthritis that hasn't improved with other treatments. The goal is to see if this combination is safe and effective in reducing joint pain and inflammation.
This study tests a new medication called AZD1163 for people with rheumatoid arthritis (RA) that hasn't responded well enough to standard treatments. It aims to see if the drug can safely reduce joint swelling and pain.
This trial tests whether combining Telitacicept and Tofacitinib can help people with rheumatoid arthritis that hasn't improved with at least two other advanced treatments. The goal is to see if these drugs work better together for hard-to-treat cases.
This study tests an investigational medicine called PTC844 in people with active rheumatoid arthritis (RA) to see if it can reduce joint inflammation and symptoms. It may be an option if you've just been diagnosed or if your current treatment isn't working well.
This trial studies an add-on treatment approach for rheumatoid arthritis (RA) in adults whose symptoms did not improve with standard “first-line” medicines. It may help people who still have active RA after trying certain disease-modifying drugs.
Hear when a new Rheumatoid arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.